Lung Treatments
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
47
NCT05426746
First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100
Phase: Phase 1
Role: Lead Sponsor
Start: Jul 5, 2022
Completion: May 18, 2023
NCT05938036
Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS
Phase: Phase 2
Start: Dec 1, 2023
Completion: Jul 1, 2027
Loading map...